About the Program:
Program Overview:
The Advances in Chronic Hepatitis C: Management and Treatment program is a comprehensive, expert review of the 67th American Association for the Study of the Liver Diseases Annual Meeting (AASLD 2016). This program consists of four components: (1) CME Internet Symposium: AASLD 2016 Review: a 1.5 hour Internet symposium that features an overview and discussion of key presentations and posters, selected by the expert faculty discussants; (2) Comprehensive Expert Review and Discussion of Key Presentations: an on-line, in-depth review of 8 of the key poster/presentations reviewed in the Internet symposium; (3) Rapid-Fire Review of AASLD 2016: a podcast that provides a brief, audio summary of the most essential data presented at the conference; and (4) From Conference to Clinic: Reviewing and Applying Data from AASLD 2016: case-based dinner meetings during which the key data from AASLD 2016 are reviewed, discussed and applied to patient care.
From Conference to Clinic: Reviewing and Applying Data From AASLD 2016 is an interactive, case-based dinner program series designed to highlight and discuss the clinical significance and application of new findings in HCV medicine presented at AASLD 2016. Because the focus of the dinner programs will be on case studies and applying the data presented at AASLD 2016 in a clinical setting, prior to attending a dinner program participants will be asked to view the CME Internet Symposium: AASLD 2016 Review, which will familiarize them with the AASLD 2016 data and serve as a comprehensive conference overview and summary. As a result of this blended learning approach, participants will gain an increased understanding of key data presented at AASLD 2016 and be better prepared to address their HCV patients' health needs and provide optimal care in a clinical setting.
All online components of the program will be accessible at www.viraled.com
This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at AASLD 2016 and it is not sanctioned by the organizers of AASLD 2016.
Target Audience:
This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HCV infection.
Educational Objectives:
After completing this activity, the participant should be better able to:
- Use in a clinical setting important findings from key studies on CHC diagnosis and treatment presented at AASLD 2016
- Employ the current treatment paradigms for CHC, including the studies and data presented at AASLD 2016 to improve patient care
- Discuss with patients and colleagues the studies and data on newer therapies for CHC presented at AASLD 2016 to decide on appropriate planning of therapy for patients with CHC
Program Dates and Locations:
Tuesday, November 29, 2016
Los Angeles, CA
|
Tuesday, December 6, 2016
Miami, FL
|
Wednesday, November 30, 2016
New York, NY
|
Tuesday, December 6, 2016
Houston, TX
|
Thursday, December 1, 2016
San Francisco, CA
|
Wednesday, December 14, 2016
Chicago, IL
|
Program Faculty:
Maurizio Bonacini, MD
Director, HIV-Liver Clinic
Department of Transplantation
California Pacific Medical Center
San Francisco, California
|
Sammy Saab, MD
Professor of Medicine and Surgery
The Pfleger Liver Institute
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, California
|
John M. Vierling, MD
Professor of Medicine
Professor of Surgery
Chief of Hepatology
Director of Advanced Liver Therapies
St. Luke’s Hospital Director of
Baylor Liver Health
Houston, Texas
|
Lennox Jeffers, MD
Chief of Hepatology
Miami VA Medical Center
Associate Chief
Center for Liver Disease
Professor of Medicine
University of Miami’s School of Medicine
Miami, Florida |
Mark Sulkowski, MD
Professor of Medicine and
Medical Director
Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland |
Schedule for All Programs:
6:00 - 6:30 PM: Check-in/Walk-in Registration
6:30 - 8:30 PM: Program and Q&A
Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc.
The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation:
The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their participation in the activity.
Sunshine Act:
As of August 1, 2013, pharmaceutical companies are required by the open payments act (AKA Sunshine Act) to account for certain transfers of value provided to physicians. The federal guidance for the Sunshine Act provides exceptions for CME expenses that meet certain criteria. We believe the program to which you are invited meets these exce ptions, and therefore we will not be collecting, nor reporting, any information gathered from this program. If federal guidance is further clarified in the future, we will then pro vide that information to the supporting pharmaceutical companies to the best of our ability.
Disclosure of Conflicts of Interest:
The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to
control the content of this activity to disclose any real or ap parent conflict of interest (COI) they may have as related to th e content of this
activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a
position to control content will be disclosed to participants prior to the start of each activity.
This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs.
This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.
|